Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Investment Securities (2022 - 2025)

Axsome Therapeutics' Gains from Investment Securities history spans 4 years, with the latest figure at -$19.4 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 544.75% year-over-year to -$19.4 million; the TTM value through Dec 2025 reached $4.7 million, down 58.39%, while the annual FY2025 figure was $4.5 million, 46.68% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$19.4 million at Axsome Therapeutics, down from $21.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $21.5 million in Q3 2025 and bottomed at -$19.4 million in Q4 2025.
  • The 4-year median for Gains from Investment Securities is $3.4 million (2024), against an average of $3.5 million.
  • The largest annual shift saw Gains from Investment Securities soared 2720.83% in 2023 before it crashed 544.75% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $931000.0 in 2022, then surged by 571.0% to $6.2 million in 2023, then tumbled by 30.29% to $4.4 million in 2024, then plummeted by 544.75% to -$19.4 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Gains from Investment Securities are -$19.4 million (Q4 2025), $21.5 million (Q3 2025), and $8.3 million (Q1 2025).